EMERYVILLE, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) — Adamas Prescription drugs, Inc. (ADMS) right this moment introduced that the compensation committee of the corporate’s board of administrators granted three new workers the choice to buy an combination of 14,500 shares of the corporate’s frequent inventory, at a per share train value of $4.70, the closing buying and selling value on November 7, and restricted inventory items to accumulate 7,250 shares of the corporate’s frequent inventory. The inventory choices and restricted inventory items vest over 4 years and have been granted pursuant to the Adamas Prescription drugs, Inc. 2016 Inducement Plan, which was authorised by the corporate’s board of administrators in March 2016 below Rule 5653(c)(4) of the Nasdaq World Marketplace for fairness grants to induce new workers to enter into employment with the corporate.
About Adamas Prescription drugs, Inc.
Adamas’ objective is to create and commercialize a brand new technology of medicines supposed to minimize the burden of continual neurologic ailments on sufferers, caregivers and society utilizing its deep understanding of time-dependent biology. The Firm is targeted on the commercialization of GOCOVRI® (amantadine) prolonged launch capsules, the primary and solely FDA-approved medication for the remedy of dyskinesia in sufferers with Parkinson’s illness receiving levodopa-based remedy, with or with out concomitant dopaminergic medicines. The Firm additionally continues to ship differentiated investigational applications, together with ADS-5102 in improvement for the remedy of strolling impairment in sufferers with a number of sclerosis. For extra details about Adamas and its distinctive method to creating medicines based mostly on time-dependent biology, please go to www.adamaspharma.com.
Vice President, Communications & Engagement